LSG2024 Targets of ¥2.5 Billion in Operating Profit and 7.9% ROIC
First written in FY2022. 4 of 9 entries say "Restated". Latest entry: FY2025.
0 other companies' latest entry also says "Reframed".
- FY2025ReframedAnnual report
「Having completed the final year of LSG (Leading to Sustainable Growth) 2024, which was announced on 24 December 2021, the Group announced a new medium-term management plan, “Make a Leap 2027: Strengthen Our Foundation and Make Further Leaps,” dated 25 June 2025.」
Following completion of LSG2024's final year, the plan was updated from the previous operating profit and ROIC targets to the management indicators under the new medium-term management plan. - FY2025-H1Further review of quantitative targetsAnnual report
「Against this backdrop, on 24 December 2021 the Group announced its medium-term management plan, LSG (Leading to Sustainable Growth) 2024, whose final year is the current consolidated fiscal year. To further enhance shareholder value, strengthen competitiveness and achieve growth, the Group is pursuing initiatives to become a company selected by investors, strengthen revenue generation through business development centered on the dispensing pharmacy business, and improve its earnings structure by further strengthening its management foundation. Due to changes in the operating environment and other factors, the Group decided to review its quantitative targets again, but there have been no changes to the basic policies or qualitative targets.」
As LSG2024 reaches its final year, the Group stated its policy of maintaining its basic policies and qualitative targets while reviewing its quantitative targets again. The revised figures were not disclosed in this filing. - FY2024Disclosure of figures following the review of quantitative targetsAnnual report
「The target management indicators on a consolidated basis for the fiscal year ending May 2025, the final year of the medium-term management plan, are as follows: Item Plan before review Plan after review Net sales ¥57.06 billion ¥60.88 billion Operating profit ¥1.88 billion ¥940 million Net income ¥880 million ¥40 million ROIC 6.8% 1.6%」
For LSG2024's quantitative targets, the net sales target was raised to ¥60.88 billion, while the operating profit, net income and ROIC targets were revised to ¥940 million, ¥40 million and 1.6%, respectively. - FY2024-Q2RestatedAnnual report
「Against this backdrop, on 24 December 2021 the Group announced its medium-term management plan, LSG (Leading to Sustainable Growth) 2024. To further enhance shareholder value, strengthen competitiveness and achieve growth, the Group is pursuing initiatives to become a company selected by investors, strengthen revenue generation through business development centered on the dispensing pharmacy business, and improve its earnings structure by further strengthening its management foundation. Due to changes in the operating environment and other factors, the Group reviewed its quantitative targets in the first quarter, but there have been no changes to the basic policies or qualitative targets.」
The Group reiterated that it would maintain LSG2024's basic policies and qualitative targets and had reviewed its quantitative targets in the first quarter. - FY2024-Q1Revision of quantitative targetsAnnual report
「Against this backdrop, on 24 December 2021 the Group announced its medium-term management plan, LSG (Leading to Sustainable Growth) 2024. To further enhance shareholder value, strengthen competitiveness and achieve growth, the Group is pursuing initiatives to become a company selected by investors, strengthen revenue generation through business development centered on the dispensing pharmacy business, and improve its earnings structure by further strengthening its management foundation. Although the Group decided to review its quantitative targets due to changes in the operating environment and other factors, there have been no changes to the basic policies or qualitative targets.」
While maintaining LSG2024's basic policies and qualitative targets, the Group stated its policy of reviewing its quantitative targets due to changes in the operating environment. The revised figures were not presented in the quarterly report. - FY2023RestatedAnnual report
「The target management indicators on a consolidated basis for the fiscal year ending May 2025, the final year of the medium-term management plan, are as follows: ・Operating profit: ¥2.5 billion ・ROIC: 7.9%」
The targets of ¥2.5 billion in operating profit and 7.9% ROIC for LSG2024 in the fiscal year ending May 2025 remain in place. - FY2023-Q3RestatedAnnual report
「On 24 December 2021, the Group announced its medium-term management plan, LSG (Leading to Sustainable Growth) 2024, and is pursuing (1) stronger initiatives to become a company chosen by investors, (2) stronger earnings generation through business expansion centred on the dispensing business, and (3) improvements to its earnings structure through further strengthening of its management foundation, with the aim of further increasing shareholder value and strengthening competitiveness to achieve growth.」
The Group continues to pursue LSG2024's three priority areas: investor value, revenue generation centered on the dispensing pharmacy business, and strengthening the management foundation. - FY2023-Q1RestatedAnnual report
「On 24 December 2021, the group announced its medium-term management plan LSG (Leading to Sustainable Growth) 2024. To further enhance shareholder value, strengthen competitiveness and achieve growth, it is promoting ① stronger initiatives to become a company chosen by investors, ② stronger earnings generation through business development centered on the pharmacy business, and ③ improvements to its earnings structure through further strengthening of its management foundation.」
The Group continues to pursue LSG2024's three priority areas: investor value, revenue generation centered on the dispensing pharmacy business, and strengthening the management foundation. - FY2022First statedAnnual report
「The target management indicators on a consolidated basis for the fiscal year ending May 2025, the final year of the medium-term management plan, are as follows: ・Operating profit: ¥2.5 billion ・ROIC: 7.9%」
For LSG2024, the Group disclosed for the first time numerical targets of ¥2.5 billion in operating profit and 7.9% ROIC for the fiscal year ending May 2025.